Key Stats for Zoetis Inc. Stock
- Current Price: $116
- Target Price: $167
- Street Target: $151
- Potential Total Return: 44.4%
- Annualized IRR: 8%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Routine veterinary visits are slowing down across the industry.
However, total spending per clinic visit recently jumped by 6%. This metric proves that pet owners are still willing to pay for premium, specialized care.
Consequently, Zoetis Inc. (ZTS) is adjusting its product strategy to match this new clinical reality.
Speaking at the KeyBanc Healthcare Forum in March 2026, CEO Kristin Peck highlighted a major near-term challenge.
The company’s blockbuster dermatology drug, Apoquel, faces “unprecedented competitive pressure.” Cheaper generic pills are currently flooding the market.
To fight back, Zoetis is pushing 3-month, long-acting injectables like Cytopoint.
This specific strategy eliminates monthly vet visit fees for pet owners.
Furthermore, it drastically improves medical compliance since owners no longer have to administer daily pills.
“If you look at Apoquel… competitors are competing against a beef-flavored chew that has 12 years of safety data,” Peck stated.
“When people launch, they’re going to launch with much lower prices than they can sustain.”
Meanwhile, the livestock division is booming. Historically, this segment grows 2% to 4% annually.
Today, it is posting mid-to-high single-digit growth.
Interestingly, Peck linked this global surge directly to GLP-1 weight-loss drugs.
Patients on these medications are consuming much more animal protein to preserve their muscle mass.
Therefore, global demand for healthy poultry, cattle, and pork is rising rapidly.
See historical and forward estimates for Zoetis Inc. stock (It’s free!) >>>
Is Zoetis Inc. Undervalued Today?
Wall Street currently seems obsessed with the generic dermatology threat. In fact, the stock suffered a severe 32.20% max drawdown earlier this year.
However, this pessimistic view completely ignores the company’s massive innovation pipeline.
The current share price of $115.67 does not accurately reflect the future of chronic animal care.
The “COVID puppies” adopted during the 2020 pandemic are getting older.
Soon, they will require specialized, high-margin treatments for cancer and organ failure.
Zoetis is uniquely positioned to capture this market.
The company is currently using artificial intelligence to build these exact therapies.
Because Zoetis owns a massive, proprietary animal genetics database, its AI software can select drug molecules with far fewer side effects than traditional research methods.
Most importantly, management expects a revolutionary kidney disease drug approval in 2027.
This single therapy targets a massive, unmet $3 billion to $4 billion Total Addressable Market.
Currently, there is absolutely no product on the market to prevent early-stage renal damage in dogs and cats.
When you compare this impending monopoly against the $151.00 Street Target, the stock looks incredibly attractive.
The market is aggressively pricing in the Apoquel patent cliff, but it is entirely ignoring the incoming chronic care pipeline.
See whether ZTS is undervalued vs peers (It’s free!) >>>
TIKR Advanced Model Analysis
The TIKR Advanced Model confirms that Zoetis remains a highly profitable compounder capable of outgrowing its short-term competitive headwinds.
- Current Price: $116
- Target Price: $167
- Potential Total Return: 44.4%
- Annualized IRR: 8%
Build a 4-year Valuation Model for ZTS for yourself (It’s free) >>>
Our Mid Case model projects a $166.98 target price. This target relies on a highly conservative 4.3% Revenue CAGR through 2031. This forecast matches management’s current 3.5% organic growth guidance perfectly. Essentially, reliable 2-3% annual price hikes will effortlessly offset the slower clinic foot traffic.
Ultimately, incredible profitability protects this valuation. The model forecasts a staggering 30.9% Net Income Margin.
Long-acting injectables cost much less to manufacture at scale than millions of daily pills. Furthermore, chronic monoclonal antibody therapies command premium pricing. By dominating these specialized treatments, Zoetis secures a defensive 8.0% annualized IRR for long-term investors.
Conclusion: Zoetis Inc. is successfully moving past the pandemic pet boom. The market is currently fixated on generic competition and slow clinic traffic. However, this ignores the highly profitable future of chronic animal care. With a booming livestock segment and a massive AI-driven pipeline targeting billion-dollar unmet needs, the $167 valuation shows that betting against the human-animal bond is a mathematical mistake.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Zoetis Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Zoetis Inc., and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Zoetis Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Zoetis Inc. on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
